March 25th, 2025
ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor
Samantha Budd Haeberlein, PhD, Joins the Board; Henrik Zetterberg, MD, PhD, Extends Advisory Role, Adding to a Preeminent Group of Multi-Disciplinary Experts Guiding ALZpath’s Innovation Initiatives
CARLSBAD, California, March 25, 2025 — ALZpath, Inc., a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced the addition of Samantha Budd Haeberlein, PhD, to its board of directors and that Henrik Zetterberg, MD, PhD, a member of the company’s advisory board, has been named Distinguished Science Advisor and will take a more active role guiding the company’s innovation initiatives.
Dr. Budd Haeberlein brings extensive experience to her role as director from the biopharmaceutical industry having served in senior management positions across neuroscience research, translational medicine, and clinical development functions at leading global companies, including Biogen and AstraZeneca. She currently serves as chief medical officer at Enigma Biomedical Group. She joins a board of directors with deep expertise across business, medicine, neuroscience, and pharmaceuticals.
ALZpath Board Chair Jerre Stead said, “We are so pleased to have Samantha, who brings a wealth of experience in biotech, Alzheimer’s disease, and in advanced treatment approaches for this devastating condition, as part of our board.”
Dr. Zetterberg became a member of the ALZpath advisory board in 2022, joining other distinguished leaders in Alzheimer’s research who serve as advisors to ALZpath. He serves as a professor of neurochemistry at the University of Gothenburg, where he leads a group using neurochemical and molecular biology methodology to identify and study the pathophysiology of neurodegenerative diseases. In addition, Zetterberg serves as a professor of neurochemistry at University College London, where he leads the Institute of Neuroscience and Physiology. He holds an appointment at the University of Wisconsin Department of Medicine, School of Medicine and Public Health, has co-authored over 2,400 publications and is a member of the panel guiding the Alzheimer’s Association Clinical Practice Guideline on the Use of Blood-based Biomarkers.
ALZpath CEO Mike Banville said, “We are extremely fortunate to have had Henrik – a world leader in neurochemistry and fluid biomarkers – involved as a key advisor for the past couple of years. As we enter the next phase of growth, we are eager for Henrik to play a more engaged advisory role. His experience will be increasingly valuable as more disease-modifying therapies become available to treat patients with Alzheimer’s and other neurological conditions.”
Other members of the ALZpath Advisory Board include:
-Advisory Board Chair Jeff Cummings, MD, ScD(HC), Research Professor at the Department of Brain Health, Director, Chambers-Grundy Center for Transformative Neuroscience at University of Nevada, Las Vegas and Principal Investigator of the Biomarker Observatory for Alzheimer’s Disease.
– Advisory Board Vice Chair Peter Snyder, PhD, Professor of Biomedical and Pharmaceutical Sciences, University of Rhode Island and Founding Editor-in-Chief for Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
– Eric Reiman, MD, ALZpath Co-founder, CEO of Banner Alzheimer’s Institute, Director of the Arizona Alzheimer’s Consortium, Senior Scientist, Neurogenomics at the Translational Genomics Research Institute (TGen), Professor of Psychiatry at the University of Arizona, and University Professor of Neuroscience at Arizona State University
– Kaj Blennow, MD, PhD, Professor and Academic Chair in Clinical Neurochemistry at the University of Gothenburg, and head of the Neurochemistry Lab at Sahlgrenska University Hospital
– Jeff Dage, PhD, Senior Research Professor of Neurology, Primary Member, Stark Neurosciences Research Institute at Indiana University School of Medicine
– Sterling Johnson, PhD, Clinical Neuropsychologist at the University of Wisconsin-Madison School of Medicine and Public Health, Principal Investigator of the Wisconsin Registry for Alzheimer’s Prevention (WRAP), and Co-PI of the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)
– Soeren Mattke, MD, DSc, Research Professor of Economics at University of Southern California (USC) and Director of the USC Brain Health Observatory
– Michael Weiner, MD, Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco and Principal Investigator of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and BrainHealthRegistry.org, Northern California Institute for Research and Education (NCIRE)
About ALZpath
ALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias. The novel ALZpath pTau217 antibody, integral to the most advanced, widely available blood-based tests to detect Alzheimer’s disease, is transforming its diagnosis and treatment monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide. To help millions of patients in need, ALZpath democratizes access to its proprietary robust antibody, which is used by researchers, clinicians, and industry partners around the world to accelerate the discovery of new treatments and improve patient care.
To learn more about the company, please visit https://alzpath.bio/ and follow us on LinkedIn.
ALZpath Media Contact
Nechama Rosengarten
Nechama.Rosengarten@finnpartners.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on ALZpath’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause ALZpath’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in ALZpath’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, ALZpath assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
